Clinical outcome of intensity modulated radiotherapy for carcinoma showing thymus-like differentiation.
OBJECTIVE
To evaluate the efficacy and toxicity of adjuvant intensity-modulated radiotherapy (IMRT) after surgery for carcinoma showing thymus-like differentiation (CASTLE).


METHODS
Between September 2008 and June 2015, 14 CASTLE patients were retrospectively enrolled. The clinical features, treatment procedure and clinical outcomes were reviewed. All patients received postoperative IMRT. The radiation doses ranged from 56Gy/28 fractions to 66Gy/33 fractions. Treatment-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0.


RESULTS
After a median follow-up period of 42 months, only one patient suffered local recurrence and distant metastasis. The most frequently seen acute toxicities were mucositis and dermatitis (grade 1-2). No grade 3-4 toxicities were observed.


CONCLUSIONS
Although based upon a small series of consecutively treated patients, our study showed that adjuvant IMRT provides satisfactory local-regional control for CASTLE, with acceptable toxicities. Further studies are still warranted to clarify our findings.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Fangfang
F
Kong
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Hongmei
H
Ying
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Ruiping
R
Zhai
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Chengrun
C
Du
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.|Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, P. R. China.
Shuang
S
Huang
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Junjun
J
Zhou
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Xiayun
X
He
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Chaosu
C
Hu
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.|Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Zhuoying
Z
Wang
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.|Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Tuanqi
T
Sun
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.|Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Qinghai
Q
Ji
D000328:Adult; D002277:Carcinoma / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery; D002454:Cell Differentiation; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
CASTLE; IMRT; carcinoma showing thymus-like differentiation; intensity-modulated radiotherapy; radiotherapy